New Eli Lilly weight loss drug has dramatic effects in clinical trial
Eli Lilly's new weight loss drug, retatrutide, has shown significant results in clinical trials, enabling patients to achieve weight loss levels comparable to bariatric surgery. Participants lost an average of 28% of their body weight over 18 months, with nearly half losing at least 30%. The drug's unique formulation may help users maintain muscle mass better than other GLP-1 medications.
- ▪Retatrutide helped patients lose an average of 28% of their body weight in a phase 3 clinical trial.
- ▪Nearly half of the participants lost at least 30% of their body weight, similar to gastric bypass surgery results.
- ▪Eli Lilly plans to seek FDA approval for retatrutide by the end of the year, depending on the outcomes of two late-stage trials.
6 outlets in our directory ran this story, first to last over 8 hours. Coverage spans 2 points on the political spectrum — 1 lean left, 4 centre.
- ▪ New obesity drug from Lilly delivers major weight loss — The Hill
- ▪ A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says — TIME — Top
- ▪ Eli Lilly's next-generation weight loss injection posted record results in obesity trial — Quartz
- ▪ New Weight Loss Drug Retatrutide Delivers Stunning Results — TODAY.com
- ▪ Eli Lilly says next-generation weight loss drug clears crucial obesity trial — US Top News and Analysis
Washington Examiner files mainly under politics. We currently carry 2,302 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Washington Examiner |
| Canonical URL | https://www.washingtonexaminer.com/policy/healthcare/4578113/eli-lilly-weight-loss-drug-dramatic-effects-in-clinical-trial/ |
| Publication time | Thu, 21 May 2026 16:32:54 +0000 |
| Retrieval time | 2026-05-21T16:35:06.371Z |
| Last seen | 2026-05-21T16:35:06.371Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | aBS1rBimYei- · 6 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
An experimental anti-obesity injection helped patients reach new levels of weight loss previously only achievable through bariatric surgery, according to new data from the pharmaceutical giant Eli Lilly. The new medication, retatrutide, appears to be the most powerful medication of its kind in a wave of injections and pills that have transformed obesity and diabetes management in recent years. Recommended Stories Surgeon general advisory raises concern about screen time for children and teenagers RFK Jr.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
